Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®)
Related news for (SLRX)
- Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
- MoBot alert highlights: NASDAQ: ACXP, NASDAQ: PCSA, NASDAQ: SLRX, NASDAQ: XTLB, NYSE: BURU (10/07/25 06:00 PM)
- MoBot alert highlights: NASDAQ: SLRX, NASDAQ: GLUE, NASDAQ: DEVS, NASDAQ: CHEK, NYSE: ATCH (09/15/25 07:00 AM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/28/25 07:00 PM
- Hot Stocks in the News – June 17, 2025